127 related articles for article (PubMed ID: 7692137)
1. Tenascin staining positivity and the survival of patients with invasive breast carcinoma.
Shoji T; Kamiya T; Tsubura A; Hamada Y; Hatano T; Hioki K; Morii S
J Surg Res; 1993 Sep; 55(3):295-7. PubMed ID: 7692137
[TBL] [Abstract][Full Text] [Related]
2. [Relationship of an extracellular matrix protein, tenascin and breast diseases].
Ishihara A; Yatani R; Sakakura T
Rinsho Byori; 1993 Oct; 41(10):1099-107. PubMed ID: 7504753
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
4. Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis.
Sugawara I; Hirakoshi J; Masunaga A; Itoyama S; Sakakura T
Invasion Metastasis; 1991; 11(6):325-31. PubMed ID: 1726610
[TBL] [Abstract][Full Text] [Related]
5. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
7. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
8. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical studies on tenascin in human yellow ligament.
Fujii Y; Yoshida H; Sakou T
In Vivo; 1993; 7(2):143-6. PubMed ID: 7689866
[TBL] [Abstract][Full Text] [Related]
11. [Detection of tenascin in stomach cancer. An immunohistochemical study].
Broll R; Kayser K; Vollmer G; Plagemann M; Bruch HP
Zentralbl Pathol; 1994 Jul; 140(2):123-8. PubMed ID: 7524650
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
13. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
14. Negative margin status improves local control in conservatively managed breast cancer patients.
Obedian E; Haffty BG
Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
[TBL] [Abstract][Full Text] [Related]
15. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
16. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
17. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and prognosis in breast cancer patients over 70 years of age].
Zhao WH; Xu BH; Li Q; Zhang P; Sun Y
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):385-8. PubMed ID: 17045008
[TBL] [Abstract][Full Text] [Related]
19. [Correlations between estrogen receptor and prognostic factors of patients with breast cancer. The Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
Tominaga T; Abe O; Izuo M; Isono K; Enomoto K; Nishi M; Fukami A; Muto T; Morioka Y; Watanabe H
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2171-6. PubMed ID: 8239682
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
